Effect of vitamin D3 on glycemic control, inflammatory markers and 24hr urine protein in patients with insufficiency and deficiency in serum vitamin D level in type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015081723656N1

Enrollment

Registered

2015-08-24

Start date

2014-07-16

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group 1: Tablets Pearl vitamin D3 -50000 one unit every week to two months. Intervention 2: Intervention group 2: control group was used placebo.

Treatment - Drugs

Placebo

Intervention group 1: Tablets Pearl vitamin D3 -50000 one unit every week to two months.

Intervention group 2: control group was used placebo.

Eligibility

Sex/Gender

All

Age

41 Years to 88 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with type 2 diabetes treated with insulin or medication to lower blood sugar levels; have a vitamin D deficiency; insulin and blood sugar-lowering drugs are used on a regular basis; during the last month are not taking calcium and vitamin D supplementation; proteinuria more than 200 mg per 24 hours urine; the serum creatinine less than 2 or GFR above 50. Exclusion criteria: type 1 diabetes; the normal level of vitamin D; not cooperating with the regular use of drugs; serum creatinine greater than 2 or GFR less than 50; D Calcium intake during the last month; unwillingness to continue to participate in the study; calcium in phosphorus above 55; calcium greater than 10, all conditions that affect the ESR, except for the lack of vitamin D.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FBS. Timepoint: Before , two and four months after the intervention. Method of measurement: Lab data.;Hemoglubin A1c. Timepoint: Before , two and four months after the intervention. Method of measurement: Lab data.;ESR. Timepoint: Before , two and four months after the intervention. Method of measurement: Lab data.;CRP. Timepoint: Before , two and four months after the intervention. Method of measurement: Lab data.;Proteinuria. Timepoint: Before , two and four months after the intervention. Method of measurement: Lab data.	—

Measure

Time frame

FBS. Timepoint: Before , two and four months after the intervention. Method of measurement: Lab data.;Hemoglubin A1c. Timepoint: Before , two and four months after the intervention. Method of measurement: Lab data.;ESR. Timepoint: Before , two and four months after the intervention. Method of measurement: Lab data.;CRP. Timepoint: Before , two and four months after the intervention. Method of measurement: Lab data.;Proteinuria. Timepoint: Before , two and four months after the intervention. Method of measurement: Lab data.

—

Secondary

Measure	Time frame
Phosphor. Timepoint: Before , two and four months after the intervention. Method of measurement: Lab data.;Calcium. Timepoint: Before , two and four months after the intervention. Method of measurement: Lab data.;Albumin. Timepoint: Before , two and four months after the intervention. Method of measurement: Lab data.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ali Momeny

Associate Professor, School of Medicine

ali.momeny@yahoo.com+98 38 3334 6692

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026